Weight Loss: Doctor-Prescribed GLP-1, Semaglutide, Tirzepatide, Phentermine & More

Choosing the Right Weight Loss Treatment

Tmates telehealth's weight loss category gives patients access to five different prescription options — the broadest range of physician-supervised weight loss treatments available through any US telehealth platform in 2026. Understanding how these five options differ in mechanism, evidence base, price, and appropriate patient profile helps you make an informed decision alongside your physician's guidance.

Compounded tirzepatide at $297/month is the clinical gold standard for maximum weight loss. Its dual GLP-1/GIP mechanism produced 22.5% average body weight reduction in SURMOUNT-1 — the largest pharmacological weight loss ever documented. At the 15mg maximum dose, 57% of participants lost ≥20% of body weight. For patients who can commit to 6–12 months of treatment and want the best possible outcomes from prescription medication, tirzepatide is the evidence-based choice. The 12-month bundle brings it to $167/mo — saving 44% versus month-to-month.

Compounded semaglutide at $249/month is the most clinically proven and best-studied option: STEP-1 documented 14.9% average weight loss over 68 weeks, and the SELECT trial (2023) additionally showed a 20% reduction in major cardiovascular events. Available in both injectable and oral formats at the same price — with all dosages from 0.25mg to 2.4mg included in one flat rate. For patients who are price-sensitive between the two GLP-1 options, or who want the most extensively studied medication, semaglutide is the appropriate starting point. See the semaglutide vs tirzepatide comparison for full trial-data analysis.

Phentermine at $149/month is the most accessible entry point to prescription weight loss. No injections, no refrigeration — once-daily oral tablet. It produces 3–7% average weight loss over a 12-week course through CNS-mediated appetite suppression. For patients where $249–$297/month is not currently accessible, or who want a short-term kickstart before committing to a longer GLP-1 program, phentermine through Tmates' program is a physician-supervised option with meaningful clinical backing. Compare: phentermine vs semaglutide, Contrave vs phentermine, Qsymia vs phentermine.

Wegovy® Rx service at $99/month and Zepbound® Rx service at $99/month are for patients who specifically want the FDA-approved brand-name product. The $99/month Tmates service fee covers clinical evaluation and prescription management only — the prescription goes to your pharmacy, where the brand-name medication is billed separately ($1,059–$1,350+/month at retail without insurance). These services are appropriate for patients with insurance coverage for brand-name GLP-1 medications or strong personal preference for FDA-approved finished products over compounded alternatives.

Clinical Evidence for GLP-1 Weight Loss

The evidence base for GLP-1 medications as a weight loss treatment is the strongest in the history of obesity pharmacotherapy. Key landmark trials:

• STEP-1 (NEJM, 2021): Semaglutide 2.4mg — 14.9% average body weight reduction at 68 weeks. 86.4% of participants lost ≥5%; 50.5% lost ≥15%.
• SURMOUNT-1 (NEJM, 2022): Tirzepatide 15mg — 22.5% average body weight reduction at 72 weeks. 57% of participants achieved ≥20% weight loss.
• SELECT (NEJM, 2023): Semaglutide reduced cardiovascular events by 20% in overweight adults without diabetes — extending the clinical case beyond weight alone.
• SURMOUNT-4 (JAMA, 2023): Continued tirzepatide after initial weight loss sustained and extended results; those who discontinued regained significant weight, supporting long-term treatment.

For condition-specific guidance, see: GLP-1 for obesity (BMI 30+), GLP-1 for PCOS weight loss, GLP-1 for prediabetes, GLP-1 for metabolic syndrome.

Is Tmates Weight Loss Right for You?

Tmates weight loss programs are appropriate for adults with BMI ≥27 with a weight-related health condition (type 2 diabetes, hypertension, high cholesterol, sleep apnea) or BMI ≥30 without additional conditions. You should not pursue GLP-1 therapy if you have personal or family history of medullary thyroid carcinoma or MEN2, if you are pregnant or planning pregnancy, or if you have active pancreatitis.

The platform's 90-second eligibility questionnaire goes to a board-certified US physician for individual review. If you're not approved, you receive a full refund — there is no cost to check your eligibility. Tmates telehealth platform serves all 50 states. Read the comprehensive Tmates review 2026 and compare Tmates against competitors: Tmates vs Medvi, Tmates vs TrimRx, Tmates vs Gala GLP. See also the complete guide to GLP-1 medications for educational context.